Form 4: Esperion Therapeutics Executive Sells Shares to Cover Tax Obligations

Chief Commercial Officer Eric Warren sold 2,433 shares of Esperion Therapeutics stock on March 18, 2025, to satisfy tax obligations related to vested restricted stock units.

Summary

• On March 18, 2025, Eric Warren, Chief Commercial Officer of Esperion Therapeutics, Inc. (ESPR), sold 2,433 shares of common stock.
• The shares were sold at a price of $1.487 per share.
• The transaction was executed to cover tax obligations arising from the vesting of restricted stock units.
• Following the sale, Warren directly owns 370,326 shares of Esperion Therapeutics.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an insider stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

Insider sales are a common occurrence, particularly to cover tax obligations related to equity compensation. The market typically analyzes these sales in the context of the overall insider sentiment and company performance.

Stakeholder Impact

• The sale of shares by an executive could be perceived neutrally or slightly negatively by shareholders, depending on the context and the size of the sale relative to the executive's holdings.

Key Dates

Keywords

Esperion Therapeutics, Eric Warren, stock sale, Form 4, insider trading, Chief Commercial Officer, ESPR, tax obligations, restricted stock units, beneficial ownership